The process of navigating the cancer care continuum can be extremely complex, confusing, and frustrating for patients and caregivers. To achieve better outcomes, patients need to not only be aware of their options, but also have a comprehensive understanding of them and be able to act accordingly and with purpose.
Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.
